MaaT Pharma, a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in patients with cancer through immune modulation, today announced the successful completion of the second pre-planned safety interim analysis of its ongoing Phase 2b PHOEBUS…
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule therapeutics for diseases with significant unmet needs, today announced the appointment of Bilal Arif as Chief Operating Officer (COO) and Linea Aspesi as Chief People Officer (CPO),…
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for neuropsychiatric disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). This…
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for the maintenance treatment of adults with extensive-stage small…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, announced two key executive appointments aimed at accelerating the development of its growing pipeline of novel antibody-drug conjugates (ADCs) and immunotherapies designed to treat difficult-to-manage solid tumors. The company has…
Prothena Corporation plc announced that its partner, Bristol Myers Squibb (BMS), has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BMS-986446 (PRX005), an investigational anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 clinical development…
C2N Diagnostics, a recognized global leader in advanced brain health diagnostics, has taken an important step forward in the fight against Alzheimer’s disease. The company has formally submitted its innovative blood test to the U.S. Food and Drug Administration (FDA)…
Serenity Mental Health Centers, one of the nation’s fastest-growing providers of psychiatric care and the largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS™) in the United States, today announced that its patients can now immediately benefit from the FDA’s…